naproxen has been researched along with oxybutynin in 11 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (oxybutynin) | Trials (oxybutynin) | Recent Studies (post-2010) (oxybutynin) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 2,607 | 619 | 1,670 |
| Protein | Taxonomy | naproxen (IC50) | oxybutynin (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.5951 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.027 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.002 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0032 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0035 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0027 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.5951 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.6 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.4288 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.792 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.0855 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.0242 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Laping, NJ; Leon, LA; Riedel, ES; Su, X | 1 |
| Branford-White, CJ; Chatterton, NP; Wu, XM; Yu, DG; Zhu, LM | 1 |
| ArgemÃ, A; Ellis, JL; Saurina, J; Tomasko, DL | 1 |
| Kaewchingduang, R; Niamlang, S; Paradee, N; Sirivat, A | 1 |
| Fang, L; Liu, C; Piao, H; Quan, P; Yang, D | 1 |
1 review(s) available for naproxen and oxybutynin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 other study(ies) available for naproxen and oxybutynin
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Pharmacologic evaluation of pressor and visceromotor reflex responses to bladder distension.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Blood Pressure; Cardiovascular System; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Female; Mandelic Acids; Mexiletine; Models, Animal; Morphine; Muscarinic Antagonists; Muscle Contraction; Muscle, Skeletal; Naproxen; Nociceptors; Pressure; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Receptors, Opioid, kappa; Receptors, Opioid, mu; Reflex; Sodium Channel Blockers; Sodium Channels; Urinary Bladder | 2008 |
Ester prodrug-loaded electrospun cellulose acetate fiber mats as transdermal drug delivery systems.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Cellulose; Drug Delivery Systems; Esters; Lactic Acid; Microscopy, Electron, Scanning; Microtechnology; Models, Biological; Naproxen; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Prodrugs; Spectroscopy, Fourier Transform Infrared; Transdermal Patch | 2010 |
Development of a polymeric patch impregnated with naproxen as a model of transdermal sustained release system.
Topics: Acrylates; Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Carbon Dioxide; Delayed-Action Preparations; Diffusion; Naproxen; Polymers; Polyvinyls; Pressure; Transdermal Patch | 2011 |
Effects of conductive polyazulene and plasticizer embedded in deproteinized natural rubber transdermal patch on electrically controlled naproxen release-permeation.
Topics: Animals; Azulenes; Dibutyl Phthalate; Drug Liberation; Electricity; Naproxen; Permeability; Plasticizers; Polymers; Rubber; Silicone Oils; Skin; Swine; Transdermal Patch | 2019 |
Enhanced Drug Loading in the Drug-in-Adhesive Transdermal Patch Utilizing a Drug-Ionic Liquid Strategy: Insight into the Role of Ionic Hydrogen Bonding.
Topics: Adhesives; Animals; Calorimetry, Differential Scanning; Crystallization; Drug Liberation; Hydrogen; Hydrogen Bonding; Ionic Liquids; Macrocyclic Compounds; Molecular Docking Simulation; Naproxen; Photoelectron Spectroscopy; Polymers; Rabbits; Skin; Skin Absorption; Solubility; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Transdermal Patch; X-Ray Diffraction | 2021 |